More light on cancer and COVID-19 reciprocal interaction

Br J Cancer. 2021 Apr;124(8):1344-1345. doi: 10.1038/s41416-020-01246-0. Epub 2021 Feb 3.

Abstract

Cancer patients are vulnerable to COVID-19 with consequences on treatment delays and on mortality rate. This Comment explores the interaction between COVID-19 and cancer with attention paid to the modulation by cancer treatments of both ADAM17 and TMPRSS2, the proteases which control ACE2 processing, the SARS-CoV-2 target.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM17 Protein / genetics*
  • Angiotensin-Converting Enzyme 2 / genetics
  • COVID-19 / complications
  • COVID-19 / epidemiology
  • COVID-19 / genetics*
  • COVID-19 / virology
  • Humans
  • Mortality
  • Neoplasms / complications
  • Neoplasms / epidemiology
  • Neoplasms / genetics*
  • Neoplasms / virology
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / pathogenicity
  • Serine Endopeptidases / genetics*

Substances

  • Angiotensin-Converting Enzyme 2
  • Serine Endopeptidases
  • TMPRSS2 protein, human
  • ADAM17 Protein
  • ADAM17 protein, human